Stockreport

MannKind at Oppenheimer: 2025 Revenue Jumps 46%, Eyes $450M+ in 2026 on Afrezza and FUROSCIX [Yahoo! Finance]

MannKind Corporation  (MNKD) 
Last mannkind corporation earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.mannkindcorp.com/press-releases
PDF revenue could top $450 million , citing Afrezza pediatric expansion, a potential FUROSCIX auto-injector and Tyvaso DPI royalties as key drivers. The inhaled nintedanib [Read more]